About this document
Development of DHES0815A HER2 Conjugate by Wentao Zhang is a document available to read on EtoBox.
The document discusses the development of DHES0815A, a novel HER2-directed antibody-drug conjugate that utilizes a reduced potency mono-alkylating agent linked to a HER2 antibody. Initial studies demonstrated its efficacy in HER2-positive cancers, but a Phase 1 trial was terminated due to delayed toxicities. The research highlights the potential of DHES0815A as an alternative treatment for HER2-positive malignancies, despite safety concerns.
- Author
- Wentao Zhang
- Language
- EN